WHO ICTRP trial
Study of Pregabalin effect on breast cancer surgery
IRCT20200502047263N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20200502047263N1 |
|---|---|
| Public title | Study of Pregabalin effect on breast cancer surgery |
| Scientific title | Study of Pregabalin Effect on Post Surgical Pain on Breast Cancer Patients Underwent Axillary Dissection: a Double Blind Randomized Clinical Trial Using Placebo |
| Primary sponsor | Tehran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Post op Pain after breast cancer surgery. Malignant neoplasm of breast |
| Interventions | Intervention 1: Intervention group: 75 mg Pregabalin 1h before surgery orally then every 12h until 15 days after surgery. Intervention 2: Control group: 75 mg Placebo 1h before surgery orally then every 12h until 15 days after surgery. |
| Registration date | May 8, 2020 |
| Target size | 250 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: